Status:
COMPLETED
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
Lead Sponsor:
Pfizer
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
Eligibility Criteria
Inclusion
- Male and female subjects aged ≥ 18, requiring intensive care treatment related to secondary nosocomial sepsis, who require potent broad spectrum intravenous antibiotic therapy.
Exclusion
- \-
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00318552
Start Date
January 1 2002
End Date
June 1 2006
Last Update
September 1 2017
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baja, Hungary
2
Research Site
Budapest, Hungary
3
Research Site
Eger, Hungary
4
Research Site
Kecskemét, Hungary